Pharmaceuticals
Ascletis Announces Poster Presentation of Phase II Study of ASC42 FXR Agonist for Functional Cure of Chronic Hepatitis B at EASL CONGRESS 2023
HANGZHOU and SHAOXING, China, June 26, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") today announces the poster presentation of ASC42, a novel farnesoid X receptor (FXR) agonist, in combination with PEGylated interferon (PEG-IFN) and entecavir (ETV) in chronic hepatitis B (...
2023-06-26 08:10
3113
Innovent and RemeGen Enter into Clinical Trial Collaboration Investigating Combination Therapy of TYVYT® (sintilimab injection) and Novel ADC Candidates for Advanced Solid Tumors in China
ROCKVILLE, Md. and SUZHOU, China, June 26, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology an...
2023-06-26 08:00
3650
Brii Biosciences Announces Entry into Definitive Agreements from Sale of its Equity Interest in Qpex Biopharma and Acquiring Exclusive Global Rights for BRII-693
Company acquires exclusive global rights of the novel lipopeptide BRII-693 for the difficult to treat MDR/XDR gram-negative bacterial infections Company returns Greater China rights to Qpex Biopharma of beta-lactamase inhibitor QPX7728-based products Company to receive ~$24M upfront cash payme...
2023-06-26 07:30
2723
Brii Bio Announces New Data from Partners Underscoring Potential for HBV Functional Cure at EASL™ Congress 2023
Late-breaking data from BRII-835 + PEG-IFN-a study demonstrate anti-HBs titers at the end of treatment were associated with sustained HBsAg loss 24 weeks after the end of treatment New data show more robust and persistent anti-HBs titers following vaccination with VBI's 3-antigen prevention vac...
2023-06-25 20:00
3599
Sciwind Biosciences to Highlight Positive Clinical Data for GLP-1 Peptide Agonist Ecnoglutide (XW003) at the American Diabetes Association (ADA) 83rd Annual Conference
* Results from three clinical studies show ecnoglutide to be safe and well-tolerated, and demonstrate robust therapeutic effects in overweight/obese and type 2 diabetes patients * On-going Phase 3 clinical trials in Chinese patients with type 2 diabetes and obesity have achieved target enroll...
2023-06-24 10:00
4612
SK pharmteco doubles viral vector production capacity in Europe
* Yposkesi, SK pharmteco's clinical and commercial viral vector manufacturing subsidiary for Cell and Gene Therapy (C>), completes its second bioproduction facility and doubles its manufacturing footprint to10,000m2, one of the largest inEurope * Operation of the second facility to kick sta...
2023-06-23 07:30
2265
Bergen Conference Marks 150 Years Since Discovery of the Leprosy Bacillus
TOKYO, June 22, 2023 /PRNewswire/ -- A two-day conference commemorating the discovery of the bacillus that causes leprosy 150 years ago took place in Bergen, Norway, on June 21-22, 2023. Organized by the Sasakawa Leprosy (Hansen's Disease) Initiative and the University of Bergen, the conference i...
2023-06-22 22:00
2375
Tagworks Pharmaceuticals Announces $65 Million in Series A Financing to Advance Click-to-Release Therapeutics
Financing round led by Ysios Capital and Gilde Healthcare with participation from Novartis Venture Fund, New Enterprise Associates, and Lightstone Ventures Unique Click-to-Release platform enables on-target activation of antibody-drug conjugates (ADCs) and immunomodulators, as well as off-target ...
2023-06-22 21:53
2765
I-Mab Announces the Appointment of Raj Kannan as CEO
GAITHERSBURG, Md. and SHANGHAI, June 22, 2023 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of pioneering immunotherapies, today announced the appointment of Mr. Raj Kannan...
2023-06-22 20:00
2498
PSYLO ANNOUNCES SPONSORED RESEARCH AGREEMENT WITH DAIICHI SANKYO TO DEVELOP NON-HALLUCINOGENIC PSYCHIATRIC THERAPIES
The Sponsored Research Agreement will help advance antidepressant treatments for patients in need SYDNEY, June 22, 2023 /PRNewswire/ -- Biotech start-up, Psylo, announced today that it has entered into a Sponsored Research Agreement with global Japanese pharmaceutical company, Daiichi Sankyo (DS...
2023-06-22 19:00
2066
Polyplastics Announces Commercial Availability of DURACON (R) POM PM Series for Medical Industry
TOKYO, June 22, 2023 /PRNewswire/ -- The Polyplastics Group is pleased to announce the commercial availability of its DURACON (R) POM (Polyoxymethylene/Acetal) PM Series for medical applications. The company will supply materials to all global regions, includingAsia such as China, India, Europe,...
2023-06-22 13:00
2715
Polyplastics Announces Commercial Availability of DURACON (R) POM PM Series for Medical Industry
TOKYO, June 22, 2023 /PRNewswire/ -- The Polyplastics Group is pleased to announce the commercial availability of its DURACON (R) POM (Polyoxymethylene/Acetal) PM Series for medical applications. The company will supply materials to all global regions, includingAsia such as China, India, Europe,...
2023-06-22 13:00
2070
BioCity Announces Initiation of a Phase 2 Trial for SC0062, a Promising ETA Receptor Antagonist for Chronic Kidney Disease
WUXI, China, June 21, 2023 /PRNewswire/ -- BioCity Biopharma, a clinical-stage biopharmaceutical company committed to developing novel and highly differentiated, modality-independent therapeutics for cancer and autoimmune disorders, today announced the initiation of a randomized, placebo-controll...
2023-06-22 08:02
2224
Dr. Yinfei Yin Joins Shanghai ChemPartner as Vice President and Head of Biology and Pharmacology
SHANGHAI, June 21, 2023 /PRNewswire/ -- ChemPartner
2023-06-21 23:07
2191
Teikoku Pharma granted FDA Fast Track Designation for TPU-006, a Novel 4-day Dexmedetomidine Transdermal System for Post Operative Pain Management
SAN JOSE, June 21, 2023 /PRNewswire/ -- Teikoku Pharma USA, a global pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for TPU-006 in managing postoperative pain. TPU-006 is an investigational 4-day dexmedetomidine transdermal...
2023-06-21 19:05
1962
Telix to Expand Late-Stage Urologic Pipeline with Acquisition of Lightpoint Medical
MELBOURNE, Australia, June 21, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire Lightpoint Medical and its SENSEI® radio-guided surgery business. Lightpoint Medical is aUnited Kingdom-based medical device...
2023-06-21 17:32
3044
Novo Nordisk Global Business Services earns the Best Place To Work certificate in India for 2023
BENGALURU, India, June 21, 2023 /PRNewswire/ -- Novo Nordisk Global Business Services (GBS) has been recently awarded as a best place to work inIndia by Best Places to Work – an international HR certification program. The program provides employers in different countries the opportunity to learn ...
2023-06-21 17:07
2415
Jadeite Medicines Receives Orphan Drug Designation for Odevixibat in Progressive Familial Intrahepatic Cholestasis (PFIC) from the Ministry of Health, Labour and Welfare of Japan and will also initiate Phase 3 Trial of Odevixibat in PFIC in Japan
TOKYO, June 20, 2023 /PRNewswire/ -- Jadeite Medicines Inc., (Jadeite Medicines) a clinical stage biopharmaceutical company headquartered inTokyo, Japan (President & CEO, Eiichi Takahashi) has received Orphan Drug Designation for odevixibat for the expected indication of PFIC from the Ministry of...
2023-06-21 09:00
2829
Everest Medicines' Partner Calliditas Therapeutics Makes Data Presentations on Nefecon at European Renal Association - European Dialysis and Transplant Association Congress (ERA-EDTA )
SHANGHAI, June 21, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company") announced today that its partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") made presentations on data from the NeflgArd Phase 3 Study at the European Renal...
2023-06-21 08:15
4548
Telix Urology Innovation Showcase to be held at The Yale Club, New York City
MELBOURNE, Australia and INDIANAPOLIS, June 21, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an outline agenda for the Company's briefing session for shareholders to be held on Wednesday, June 21, 2023, at The Yale Club in New York City, from 8.3...
2023-06-21 06:31
2740
Week's Top Stories
Most Reposted
QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology
[Picked up by 303 media titles]
2024-11-26 18:49ITAP 2024 sets the stage for a more connected advanced factory ecosystem with focus on AI, advanced robotics and sustainability
[Picked up by 296 media titles]
2024-11-28 17:24Southeast Asian Consumers Raise Online Security Concerns, New GSMA Survey Shows
[Picked up by 296 media titles]
2024-11-26 13:00MediSun Energy Raises $8.75M Seed Round with Vynn Capital to Drive MENA Expansion and Advance Osmotic Energy Innovation
[Picked up by 280 media titles]
2024-11-25 10:00
Mentech at COP29: Showing the Eco-friendly Lifestyle with Technological Innovation
[Picked up by 275 media titles]
2024-11-29 20:33
Most Read
Chinese path to modernization a model for Global South, experts say
2024-11-23 15:35
14553
SUNLU Formnext 2024 Event Highlights: From Functional Filaments to FilaDryer E2
2024-11-23 21:00
10661
Innovative technology and applications recognised with Hong Kong ICT Awards 2024
2024-11-23 02:02
8491
